glp-1 agonist eli lilly Drugmaker announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports. https://abcnewslive.visitlink.me/pYGbNh ADA 2026 confirmed what many
Description
10.1186/s12902-024-01775-2 69 SommE.MontandonS
48,49 Investigating GLP-1 agonism could provide critical insights into restoring metabolic homeostasis in aging tissues and may expand the therapeutic scope of GLP-1 RAs beyond their current indications
Lancet 2021;397:173648.ArticlePubMed 101
J., Zou, L
It helps manage blood sugar levels and has been noted for its additional benefit of promoting weight loss
In the OASIS 4 randomized, placebo-controlled trial, oral semaglutide demonstrated statistically significant and clinically meaningful reductions in body weight (~1417%) compared with placebo, consistent with the GLP-1 mechanism of action
